Literature DB >> 21625165

Stereotactic body radiation therapy for thoracic cancers: recommendations for patient selection, setup and therapy.

Robert Timmerman, John Heinzerling, Ramzi Abdulrahman, Hak Choy, John L Meyer.   

Abstract

Advanced technologies have facilitated the development of stereotactic body radiation therapy (SBRT) programs capable of delivering ablative radiation doses for the control of lung cancers. To date, experience with these programs has been highly favorable, as reflected in the results of careful clinical trials. The medically inoperable lung cancer patient, lacking more effective options, has served as the initial clinical base to test SBRT; the therapeutic outcomes have confirmed a significant role for this approach. For many patient groups, SBRT may become a noninvasive alternative to some thoracic surgeries, especially ones with more limited therapeutic goals such as wedge resection. Despite these results, long-term evaluation of the cases treated is required to allow greater understanding of the limitations and contributions of this new modality. The successful delivery of SBRT requires the development of a comprehensive, specialized clinical program providing advanced technology and the technical expertise of physicians, physicists and therapists specially trained in SBRT applications. To achieve successful clinical outcomes, careful patient selection and attention to therapy design and delivery are required since exacting clinical procedures are involved. This chapter will outline many details essential for establishing an effective SBRT program in clinical practice.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2011        PMID: 21625165     DOI: 10.1159/000322503

Source DB:  PubMed          Journal:  Front Radiat Ther Oncol        ISSN: 0071-9676


  10 in total

1.  LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective.

Authors:  S Adebahr; S Collette; E Shash; M Lambrecht; C Le Pechoux; C Faivre-Finn; D De Ruysscher; H Peulen; J Belderbos; R Dziadziuszko; C Fink; M Guckenberger; C Hurkmans; U Nestle
Journal:  Br J Radiol       Date:  2015-04-15       Impact factor: 3.039

2.  Phase I/II Study of Stereotactic Body Radiation Therapy for Pulmonary Metastases in Pediatric Patients.

Authors:  Kevin X Liu; Yu-Hui Chen; David Kozono; Raymond H Mak; Patrick J Boyle; Katherine A Janeway; Elizabeth A Mullen; Karen J Marcus
Journal:  Adv Radiat Oncol       Date:  2020-09-23

3.  Patterns of Pretreatment Diagnostic Assessment in Patients Treated with Stereotactic Body Radiation Therapy (SBRT) for Non-Small Cell Lung Cancer (NSCLC): Special Characteristics in the COVID Pandemic and Influence on Outcomes.

Authors:  Felix-Nikolai Oschinka Jegor Habermann; Daniela Schmitt; Thomas Failing; Jann Fischer; David Alexander Ziegler; Laura Anna Fischer; Niklas Josua Alt; Julian Muster; Sandra Donath; Andrea Hille; Markus Anton Schirmer; Manuel Guhlich; Rami A El Shafie; Stefan Rieken; Martin Leu; Leif Hendrik Dröge
Journal:  Curr Oncol       Date:  2022-02-13       Impact factor: 3.677

4.  Dosimetric selection for helical tomotherapy based stereotactic ablative radiotherapy for early-stage non-small cell lung cancer or lung metastases.

Authors:  Alexander Chi; Zhongxing Liao; Nam P Nguyen; Jiahong Xu; James S Welsh; Si Young Jang; Carol Howe; Ritsuko Komaki
Journal:  PLoS One       Date:  2012-04-25       Impact factor: 3.240

5.  Outcomes and toxicity of stereotactic body radiation therapy for advanced stage ultra-central non-small cell lung cancer.

Authors:  Yang Cong; Bing Sun; Junliang Wang; Xiangying Meng; Liang Xuan; Junjian Zhang; Jiannan Liu; Ge Shen; Shikai Wu
Journal:  Thorac Cancer       Date:  2019-06-11       Impact factor: 3.500

6.  Stereotactic body radiation therapy for the treatment of pleural metastases in patients with thymoma: a retrospective review of 22 patients.

Authors:  Giulia Pasquini; Claudia Menichelli; Gabriella Pastore; Franco Casamassima; Maria Grazia Fabrini; Sabrina Cappelli; Simona Valleggi; Maurizio Lucchesi; Marco Lucchi; Roberta Ricciardi; Michelangelo Maestri; Melania Guida; Antonio Chella; Iacopo Petrini
Journal:  J Thorac Dis       Date:  2021-11       Impact factor: 2.895

Review 7.  Stereotactic ablative radiotherapy in the UK: current status and developments.

Authors:  P Jain; A Baker; G Distefano; A J D Scott; G J Webster; M Q Hatton
Journal:  Br J Radiol       Date:  2013-07-19       Impact factor: 3.039

8.  The sensitivity of gamma-index method to the positioning errors of high-definition MLC in patient-specific VMAT QA for SBRT.

Authors:  Jung-In Kim; So-Yeon Park; Hak Jae Kim; Jin Ho Kim; Sung-Joon Ye; Jong Min Park
Journal:  Radiat Oncol       Date:  2014-07-28       Impact factor: 3.481

9.  Statistical Determination of the Gating Windows for Respiratory-Gated Radiotherapy Using a Visible Guiding System.

Authors:  Se An Oh; Ji Woon Yea; Sung Kyu Kim
Journal:  PLoS One       Date:  2016-05-26       Impact factor: 3.240

10.  Four-year follow-up outcomes after stereotactic body radiation therapy for central early-stage non-small cell lung cancer.

Authors:  Xiaojiang Sun; Yefei Li; Yaoyao Zhu; Qian Li; Xiaoshuai Yuan; Qingren Lin; Denghu Weng; Qinghua Xu; Hui Liu; Yaping Xu
Journal:  Transl Lung Cancer Res       Date:  2020-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.